Comprehensive Insights Provided into the Epidemiology Segments and Forecasts, the Future Growth Potential of Diagnosis Rate, Disease Progression, and Diagnostic GuidelinesDublin, Dec. 05, 2024 (GLOBE ...
Switch Therapeutics Inc. has announced its first development candidate, a liver-sparing APOE (apolipoprotein E) RNAi therapy for treatment of Alzheimer’s disease in APOE4 carriers. Switch’s ...
AstraZeneca's IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...
A new editorial was published in Oncotarget's Volume 15 on November 22, 2024, entitled "B7-H4: A potential therapeutic target in adenoid cystic carcinoma." ...